{
    "nct_id": "NCT05178888",
    "official_title": "A Phase 1/1b Trial of MRTX849 in Combination With Palbociclib in Patients With Advanced Solid Tumors With KRAS G12C Mutation",
    "inclusion_criteria": "* Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation\n* Unresectable or metastatic disease.\n* No available treatment with curative intent\n* Adequate organ function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of significant toxicity on prior KRAS G12C or CDK4/6 inhibitor therapies\n* History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter the absorption of study treatment or result in an inability to swallow\n* Other active cancer\n* Cardiac abnormalities",
    "miscellaneous_criteria": ""
}